A Mitochondria-related Signature for Predicting Immune Microenvironment and Therapeutic Response in Osteosarcoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 19

PMID 36531021

Authors

Lina Zhang

Song Wu

Junjie Huang

Yanbin Shi

Yuesong Yin

Xu Cao

Affiliations

Soon will be listed here.

Abstract

Background: Osteosarcoma remains to be the most devastating malignant tumor in children and teenagers. Mitochondria have also been proven to play critical roles in osteosarcoma. However, a mitochondria-related signature has been established in osteosarcoma to comprehensively evaluate the pathogenic roles and regulatory roles of mitochondria in osteosarcoma.

Methods: In this study, osteosarcoma samples' transcriptome data and clinical information were collected from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Gene Expression Omnibus (GEO) databases. A comprehensive bioinformatics analysis was performed on the samples at the bulk RNA sequencing level and single-cell RNA sequencing (scRNA-seq) level. EdU, Transwell, and immunohistochemistry (IHC) were performed on PCCB.

Results: A mitochondria-related signature was constructed in osteosarcoma patients. The prognostic value of the mitochondria-related signature was explored. The predictive value of the mitochondria-related signature in the immune microenvironment and chemotherapy agents was explored. The association between mitochondria and immunity in the tumor microenvironment of osteosarcoma at the scRNA-seq level was investigated. The tumorigenic role of the critical mitochondria-related gene, PCCB, was verified by validation.

Conclusion: In conclusion, a mitochondria-related signature was developed in osteosarcoma with solid predictive values in the immune microenvironment, chemotherapy agents, and prognosis.

Citing Articles

Construction and validation of a prognostic signature using WGCNA-identified key genes in osteosarcoma for treatment evaluation.

Chen Z, Ni R, Hu Y, Yang Y, Chen J, Tian Y Transl Cancer Res. 2025; 14(1):254-271.

PMID: 39974409 PMC: 11833431. DOI: 10.21037/tcr-24-1398.

Targeting the mitochondrial protein YME1L to inhibit osteosarcoma cell growth in vitro and in vivo.

Sun X, Shi C, Dai J, Zhang M, Pei D, Yang L Cell Death Dis. 2024; 15(5):346.

PMID: 38769124 PMC: 11106333. DOI: 10.1038/s41419-024-06722-6.

Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.

Kong Y, Li X, Zhang H, Fu B, Jiang H, Yang H Cell Death Dis. 2024; 15(1):57.

PMID: 38228583 PMC: 10791695. DOI: 10.1038/s41419-024-06444-9.

Identification of mitochondrial-related signature and molecular subtype for the prognosis of osteosarcoma.

Zhao X, Zhang J, Liu J, Chen Q, Cai C, Miao X Aging (Albany NY). 2023; 15(22):12794-12816.

PMID: 37976137 PMC: 10713410. DOI: 10.18632/aging.205143.

The exploration of mitochondrial-related features helps to reveal the prognosis and immunotherapy methods of colorectal cancer.

Xie Y, Jiang H Cancer Rep (Hoboken). 2023; 7(1):e1914.

PMID: 37903487 PMC: 10809275. DOI: 10.1002/cnr2.1914.

References

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Morishita M, Kawamoto T, Hara H, Onishi Y, Ueha T, Minoda M . AICAR induces mitochondrial apoptosis in human osteosarcoma cells through an AMPK-dependent pathway. Int J Oncol. 2016; 50(1):23-30. PMC: 5182012. DOI: 10.3892/ijo.2016.3775. View

Soon P, Libe R, Benn D, Gill A, Shaw J, Sywak M . Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Ann Surg. 2007; 247(1):157-64. DOI: 10.1097/SLA.0b013e318153ff55. View

Wang Y, Cai N, Wu X, Cao H, Xie L, Zheng P . OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway. Cell Death Dis. 2013; 4:e760. PMC: 3763434. DOI: 10.1038/cddis.2013.272. View

Toki S, Yoshimaru T, Matsushita Y, Aihara H, Ono M, Tsuneyama K . The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3-PHB2 complex formation. Cancer Sci. 2021; 112(10):4208-4219. PMC: 8486206. DOI: 10.1111/cas.15099. View

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D . Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):248-262. DOI: 10.1016/j.celrep.2016.12.019. View

Luo Y, Ma J, Lu W . The Significance of Mitochondrial Dysfunction in Cancer. Int J Mol Sci. 2020; 21(16). PMC: 7460667. DOI: 10.3390/ijms21165598. View

Liu Z, Wang H, Hu C, Wu C, Wang J, Hu F . Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma. Cell Death Dis. 2021; 12(2):164. PMC: 7870858. DOI: 10.1038/s41419-021-03449-6. View

Lee J, Lee H, Woo S, Jang H, Jeon Y, Kim H . Overall survival of pancreatic ductal adenocarcinoma is doubled by deletion in the KPC mouse. Theranostics. 2021; 11(7):3472-3488. PMC: 7847681. DOI: 10.7150/thno.53935. View

10.

Zhou Y, Li X, Guan A, Zhou H, Zhu Y, Wang R . EPHX2 Inhibits Colon Cancer Progression by Promoting Fatty Acid Degradation. Front Oncol. 2022; 12:870721. PMC: 9005964. DOI: 10.3389/fonc.2022.870721. View

11.

Mehta M, Weinberg S, Chandel N . Mitochondrial control of immunity: beyond ATP. Nat Rev Immunol. 2017; 17(10):608-620. DOI: 10.1038/nri.2017.66. View

12.

Xu K, Chen G, Li X, Wu X, Chang Z, Xu J . MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling. Sci Rep. 2017; 7:41718. PMC: 5296837. DOI: 10.1038/srep41718. View

13.

Ritter J, Bielack S . Osteosarcoma. Ann Oncol. 2010; 21 Suppl 7:vii320-5. DOI: 10.1093/annonc/mdq276. View

14.

Czabotar P, Lessene G, Strasser A, Adams J . Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2013; 15(1):49-63. DOI: 10.1038/nrm3722. View

15.

Zhang H, Zhang N, Wu W, Zhou R, Li S, Wang Z . Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma. Brief Bioinform. 2022; 23(6). DOI: 10.1093/bib/bbac386. View

16.

Jafari F, Javdansirat S, Sanaie S, Naseri A, Shamekh A, Rostamzadeh D . Osteosarcoma: A comprehensive review of management and treatment strategies. Ann Diagn Pathol. 2020; 49:151654. DOI: 10.1016/j.anndiagpath.2020.151654. View

17.

Rambold A, Pearce E . Mitochondrial Dynamics at the Interface of Immune Cell Metabolism and Function. Trends Immunol. 2017; 39(1):6-18. DOI: 10.1016/j.it.2017.08.006. View

18.

Allen E, Ulanet D, Pirman D, Mahoney C, Coco J, Si Y . Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. Cell Rep. 2016; 17(3):876-890. DOI: 10.1016/j.celrep.2016.09.052. View

19.

Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner H . Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017; 14(10):979-982. PMC: 5764547. DOI: 10.1038/nmeth.4402. View

20.

Sabharwal S, Schumacker P . Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?. Nat Rev Cancer. 2014; 14(11):709-21. PMC: 4657553. DOI: 10.1038/nrc3803. View